Efficacy and Safety of CT-P13 (Infliximab Biosimilar) over Two Years in Patients with Ankylosing Spondylitis: Comparison Between Continuing with CT-P13 and Switching from Infliximab to CT-P13

被引：0

作者：

Park, Won ^{[1
]}

Miranda, Pedro ^{[2
,3
]}

Brzosko, Marek ^{[4
]}

Wiland, Piotr ^{[5
]}

Gutierrez-Urena, Sergio ^{[6
]}

Mikazane, Helena ^{[7
]}

Lee, Yeon-Ah ^{[8
]}

Smiyan, Svitlana ^{[9
]}

Lim, Mie-Jin ^{[1
]}

Kadinov, Vladimir ^{[10
]}

Abud-Mendoza, Carlos ^{[11
,12
]}

Son, YoungKi ^{[13
]}

Yoo, Dae-Hyun ^{[14
]}

Braun, Juergen ^{[15
]}

机构：

[1] Inha Univ Hosp, Inchon, South Korea

[2] Univ Chile, Santiago, Chile

[3] Ctr Estudios Reumatol, Santiago, Chile

[4] Pomeranian Med Univ, Dept Rheumatol & Internal Dis, Szczecin, Poland

[5] Med Univ Wroclaw, Wroclaw, Poland

[6] Antiguo Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico

[7] Outpatient Clin ORTO, Riga, Latvia

[8] Kyung Hee Univ, Seoul, South Korea

[9] Ternopil Univ Hosp, Municipal Inst Ternopil Reg Council, Ternopol, Ukraine

[10] Multiprofile Hosp Act Treatment Sv Marina, Varna, Bulgaria

[11] Univ Autonoma San Luis Potosi, Hosp Cent, San Luis Potosi, Mexico

[12] Univ Autonoma San Luis Potosi, Fac Med, San Luis Potosi, Mexico

[13] CELLTRION, Inchon, South Korea

[14] Hanyang Univ, Hosp Rheumat Dis, Seoul 133791, South Korea

[15] Rheumazentrum Ruhrgebiet, Herne, Germany

来源：

ARTHRITIS AND RHEUMATISM | 2013年 / 65卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

L15

引用

页码：3326 / 3326

页数：1

共 50 条

[1] Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Yoo, Dae Hyun
Prodanovic, Nenad
Jaworski, Janusz
Miranda, Pedro
Ramiterre, Edgar
Lanzon, Allan
Baranauskaite, Asta
Wiland, Piotr
Abud-Mendoza, Carlos
Oparanov, Boycho
Smiyan, Svitlana
Kim, HoUng
Lee, Sang Joon
Kim, SuYeon
Park, Won
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 355 - 363
[2] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) Over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.
不详
ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3319 - 3319
[3] A Review of CT-P13: An Infliximab Biosimilar
Kate McKeage
BioDrugs, 2014, 28 : 313 - 321
[4] A Review of CT-P13: An Infliximab Biosimilar
McKeage, Kate
BIODRUGS, 2014, 28 (03) : 313 - 321
[5] Biosimilar CT-P13 comparable to infliximab in active RA
Nature Reviews Rheumatology, 2013, 9 (7) : 382 - 382
[6] Infliximab biosimilar CT-P13 in Crohn's disease
Gecse, Krisztina B.
D'Haens, Geert R.
LANCET, 2019, 393 (10182): : 1671 - 1672
[7] Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
Park, Won
Yoo, Dae Hyun
Miranda, Pedro
Brzosko, Marek
Wiland, Piotr
Gutierrez-Urena, Sergio
Mikazane, Helena
Lee, Yeon-Ah
Smiyan, Svitlana
Lim, Mie-Jin
Kadinov, Vladimir
Abud-Mendoza, Carlos
Kim, HoUng
Lee, Sang Joon
Bae, YunJu
Kim, SuYeon
Braun, Juergen
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) : 346 - 354
[8] CT-P13 biosimilar is non-inferior to infliximab
Dickson I.
Nature Reviews Gastroenterology & Hepatology, 2019, 16 (6) : 326 - 326
[9] Infliximab biosimilar CT-P13 for inflammatory bowel disease
Bonovas, Stefanos
Peyrin-Biroulet, Laurent
Danese, Silvio
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 373 - 375
[10] META-ANALYSIS OF THE SAFETY DATA BETWEEN INFLIXIMAB BIOSIMILAR (CT-P13) AND INNOVATOR INFLIXIMAB IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS
Park, W.
Yoo, D. H.
Suh, C. H.
Shim, S. C.
Lee, S. J.
Lee, S. Y.
Park, J. H.
Bae, Y. M.
Kim, S. H.
Lee, S. G.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1039 - 1039

← 1 2 3 4 5 →